Optilamid (Brinzolamide)

Brinzolamide, the active ingredient in Optilamid, is a carbonic anhydrase inhibitor presented as a 1% ophthalmic solution for topical ocular use. It lowers intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension, helping to preserve visual function.

GNH USA supplies Optilamid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant documentation for global distribution. Our supply chain supports timely delivery across Europe, Asia and the Americas, ensuring product integrity throughout transport.

Brinzolamide is a carbonic anhydrase inhibitor used to lower intra‑ocular pressure in glaucoma‑related conditions.

- Open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression - Ocular hypertension: lowers pressure to prevent conversion to glaucoma - Pseudoexfoliative glaucoma: adjunct therapy to control pressure spikes - Secondary glaucoma: helps maintain target intra‑ocular pressure when other agents are insufficient - Post‑laser trabeculoplasty: supports sustained pressure reduction after laser treatment

Common side effects are generally mild and transient, reflecting local ocular exposure.

Common Side Effects: - Blurred vision: temporary visual disturbance after instillation - Transient eye irritation: mild burning or stinging sensation - Altered taste: bitter taste sensation due to nasolacrimal drainage - Mild conjunctival hyperemia: slight redness of the eye

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): requires immediate medical attention - Corneal edema: swelling of the cornea affecting vision - Significant decrease in visual acuity: notable loss of sharpness - Uveitis: inflammation of the uveal tract that may need treatment

Before using Optilamid, consider the following safety measures.

- Pregnancy: safety not established; use only if potential benefit justifies the risk - Breastfeeding: unknown excretion in milk; weigh maternal benefit against infant risk - Renal impairment: monitor intra‑ocular pressure response and adjust therapy as needed - Sulfonamide allergy: avoid due to structural similarity that may trigger cross‑reaction - Concomitant carbonic anhydrase inhibitors: may increase systemic exposure and adverse effects - Store at room temperature: keep in original container, protect from light and moisture

Brinzolamide may interact with other medications; awareness of potential interactions helps maintain safety.

Major Interactions (Avoid): - Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): additive intra‑ocular pressure reduction may cause hypotony - Sulfonamide antibiotics (e.g., sulfamethoxazole): risk of cross‑reactivity in sulfonamide‑sensitive patients

Moderate Interactions (Monitor Closely): - Topical beta‑blockers: combined effect may increase risk of bradycardia or hypotension - Topical prostaglandin analogues: monitor for heightened ocular irritation - Systemic diuretics: may influence electrolyte balance and affect ocular fluid dynamics